Drugs / Talsaclidine
Talsaclidine
also known as
[14C]talsaclidine · Talsaclidina · Talsaclidine (Free Base) · talsaclidine base · TALSACLIDINE FUMARATE · WAL 2014 FU · WAL2014
Small molecule targets CHRM1, CHRM2, CHRM3 via activation
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02264093 | Nov 1999 → Feb 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02264054 | Feb → Mar 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02264067 | Jul → Nov 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02249351 | Dec 1999 → May 2000 | Alzheimer disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT02249403 | Jan 1999 → Jan 2000 | Alzheimer disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02248116 | May 1999 → Sep 2000 | Alzheimer disease | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Talsaclidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02264093 ↗ |
| Known as | [14C]talsaclidine | “Drug: [14C]talsaclidine, oral” NCT02264054 ↗ |
| Known as | Talsaclidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111051 ↗ |
| Known as | Talsaclidine (Free Base) | “Efficacy and Safety of 6, 12, 24, and 36 mg Tid po and 36 mg Bid po Talsaclidine (Free Base) for 12 Weeks” NCT02249403 ↗ |
| Known as | talsaclidine base | “symptomatic efficacy of talsaclidine base on ADAScog” NCT02249403 ↗ |
| Known as | TALSACLIDINE FUMARATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111051 ↗ |
| Known as | WAL 2014 FU | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111051 ↗ |
| Known as | WAL2014 | “Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers” NCT02264067 ↗ |
| Action | Activate | “Muscarinic acetylcholine receptor M2 partial agonist” CHEMBL2111051 ↗2“Muscarinic acetylcholine receptor M3 partial agonist” CHEMBL2111051 ↗ “Muscarinic acetylcholine receptor M1 agonist” CHEMBL2111051 ↗ |
| Modality | Small molecule | — CHEMBL2111051 ↗ |
| Route | Oral | “Oral Administration” NCT02248116 ↗ |
| Target | CHRM1 | “Muscarinic acetylcholine receptor M1 agonist” CHEMBL2111051 ↗ |
| Target | CHRM2 | “Muscarinic acetylcholine receptor M2 partial agonist” CHEMBL2111051 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 partial agonist” CHEMBL2111051 ↗ |